Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.... more >

Latest Newsmore >
03/23/17
Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT® Launch Success
On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 Conference Call Today at 10:00 a.m. ET 2016 Key Events: Sales for full-year 2016 increased 23% compared to 2015 Closed $150 million follow-on public offering and subsequent underwriters option to purchase additional $22.5 million The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter on the New Drug Application (NDA) for investigational therapeutic, lutetium Lu 177 dotatate... 
03/15/17
Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23
Conference Call at 10:00 a.m. ET SAINT-GENIS-POUILLY, France, March 15, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the Company will report its financial results for the fiscal year ended December 31, 2016, on March 23. Stefano Buono, Chief Executive Officer and Heinz Mäusli, Chief Financial Officer will host a conference call at 10:00 a.m. ET to... 
03/06/17
Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS
SAINT-GENIS-POUILLY, France, March 06, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that quality of life findings from the pivotal NETTER-1 Phase III study investigating the treatment of Lutetium Lu 177 Dotatate in patients with somatostatin receptor positive midgut neuroendocrine tumors (midgut NETs) will be presented at the 14th Annual Conference of the ... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources